ACE-031 – 1mg

Myostatin Ligand Trap — Functions as a circulating decoy receptor that binds and neutralizes myostatin and related growth inhibitors (activins, BMPs) before they reach muscle tissue, effectively removing the body’s primary biological brake on skeletal muscle development. Clinically Documented Muscle Growth — Phase 1 trials in healthy subjects reported approximately 3.3% lean body mass gain and 5.1% increase in quadriceps volume within just 29 days following a single dose — without any exercise intervention. Broad Anabolic Signaling Pathway Coverage — Unlike targeted myostatin antibodies, ACE-031 blocks multiple members of the TGF-β superfamily simultaneously, inhibiting Smad2/3 phosphorylation and the ERK1/2 atrophy pathway across both slow-twitch and fast-twitch muscle fiber types. Bone & Metabolic Research Applications — Beyond muscle, ACE-031 has shown preclinical implications for skeletal remodeling, oxidative metabolism optimization (via PGC-1α and PPARβ upregulation), and conditions of muscle wasting such as Duchenne muscular dystrophy and sarcopenia — though clinical development was paused due to vascular side effects.